D-0354-2023 Class III Terminated
FDA drug recall D-0354-2023 was initiated by Sciegen Pharmaceuticals Inc on Feb 17, 2023 and is designated Class III. Reason for recall: Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles. The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 4,392 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 8, 2023
- Initiation Date
- Feb 17, 2023
- Termination Date
- Jun 17, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 4,392 bottles
Product description
Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.
Reason for recall
Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.
Distribution pattern
Nationwide in the USA and Puerto Rico
Code information
Lot # G177092, Exp. 11/24
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0354-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026